'Gray Market' Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings

(MedPage Today) -- People who took "gray market" compounded retatrutide, an investigational triple hormone receptor agonist, achieved less weight loss with up to 12 months of treatment than clinical trial participants, a preprint study suggested...